We are live on ! Find out more
VCYT icon

Veracyte

195 hedge funds and large institutions have $1.37B invested in Veracyte in 2019 Q2 according to their latest regulatory filings, with 63 funds opening new positions, 71 increasing their positions, 50 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 63 | Existing positions closed: 14

42% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 50

39% more capital invested

Capital invested by funds: $983M → $1.37B (+$385M)

31% more funds holding

Funds holding: 149195 (+46)

4.45% more ownership

Funds ownership: 95.54%99.99% (+4.5%)

0% more funds holding in top 10

Funds holding in top 10: 77 (0)

2% less call options, than puts

Call options by funds: $2.08M | Put options by funds: $2.12M

Holders
195
Holders Change
+46
Holders Change %
+30.87%
% of All Funds
4.24%
Holding in Top 10
7
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.15%
New
63
Increased
71
Reduced
50
Closed
14
Calls
$2.08M
Puts
$2.12M
Net Calls
-$39K
Net Calls Change
+$1.11M
Name Holding Trade Value Shares
Change
Change in
Stake
Norges Bank
101
Norges Bank
Norway
$1.14M +$999K +40,000 New
State of Wisconsin Investment Board
102
State of Wisconsin Investment Board
Wisconsin
$1.11M +$22.5K +900 +2%
UBS Group
103
UBS Group
Switzerland
$1.06M +$889K +35,579 +2,238%
Connor, Clark & Lunn Investment Management (CC&L)
104
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.03M -$393K -15,750 -30%
HIM
105
Hillsdale Investment Management
Ontario, Canada
$1.02M +$165K +6,600 +23%
MWNA
106
Marshall Wace North America
New York
$958K +$839K +33,598 New
SO
107
STRS Ohio
Ohio
$909K -$50K -2,000 -6%
AIA
108
Affinity Investment Advisors
California
$894K -$129K -5,153 -14%
GAM
109
Gotham Asset Management
New York
$890K +$780K +31,232 New
BC
110
Birchview Capital
Vermont
$877K -$99.9K -4,000 -12%
RCAG
111
Rehmann Capital Advisory Group
Michigan
$872K +$605K +24,209 +380%
GPGA
112
Grandeur Peak Global Advisors
Utah
$859K -$342K -13,689 -31%
AIG
113
American International Group
New York
$845K +$289K +11,580 +64%
OAM
114
Oberweis Asset Management
Illinois
$821K -$267K -10,700 -27%
Manulife (Manufacturers Life Insurance)
115
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$819K +$248K +9,917 +53%
Royal Bank of Canada
116
Royal Bank of Canada
Ontario, Canada
$807K +$664K +26,586 +1,538%
UBS AM
117
UBS AM
Illinois
$793K +$695K +27,818 New
PAM
118
Panagora Asset Management
Massachusetts
$777K +$252K +10,098 +59%
BA
119
Boston Advisors
Massachusetts
$720K +$631K +25,254 New
FHB
120
First Hawaiian Bank
Hawaii
$685K -$54.1K -2,165 -8%
TI
121
Trexquant Investment
Connecticut
$673K +$590K +23,607 New
William Blair & Company
122
William Blair & Company
Illinois
$640K +$180K +7,200 +47%
Envestnet Asset Management
123
Envestnet Asset Management
Illinois
$638K +$559K +22,387 New
BC
124
Brinker Capital
Pennsylvania
$616K +$540K +21,604 New
Principal Financial Group
125
Principal Financial Group
Iowa
$590K +$517K +20,707 New

VCYT Hedge Fund Activity: Q2 2019 in Review

195 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Veracyte (VCYT) for Q2 2019, worth a combined $1.37B — up 39% from $983M a quarter earlier.

Buyers outnumbered sellers: 63 funds opened new VCYT positions and 14 closed out — a net gain of 49 holders — while 71 added to existing stakes and 50 trimmed.

The largest buyer was Invesco, adding an estimated $59.7M. The largest seller was Versant Venture Management, cutting an estimated $30.1M.

  • 195 institutional investors held Veracyte (VCYT) as of Q2 2019, up from 149 in Q1 2019.
  • Funds reported $1.37B of Veracyte stock for Q2 2019, up 39% quarter-over-quarter.
  • 63 funds opened new Veracyte positions in Q2 2019 and 14 closed out, a net change of +49 holders.
  • The largest Veracyte buyer in Q2 2019 was Invesco, an estimated $59.7M added.
  • The largest Veracyte seller in Q2 2019 was Versant Venture Management, an estimated $30.1M sold.

Based on aggregated 13F filings for Q2 2019.